Company Focus
Astellas Pharma
Latest Astellas Pharma News
Pharmaceutical
Japanese pharma major Otsuka Holdings and US biotech Ionis Pharmaceuticals have reported positive top-line results from the Phase III FUSION study of ulefnersen, an RNA-targeted therapy for a rare inherited form of amyotrophic lateral sclerosis (ALS). The readout is the first from a placebo-controlled study in the genetic subtype. 23 September 2026
Related News
Insights
Company Spotlight
A UK life science investor, listed in London and managed by a team the Wellcome Trust founded in 2012, that builds and funds biotech companies from British science and is now focused on returning at least £250 million ($336.8 million) to shareholders from a portfolio of 15 companies.
Latest News & Features of interest to Astellas Pharma
Pharmaceutical
Belgian pharma trade group pharma.be welcomes the new Belgian Cancer Plan 2026-2036. The innovative biopharmaceutical sector has been advocating for a new cancer plan for years and is pleased that a framework is now in place to further strengthen the fight against cancer in Belgium. 12 October 2026
Pharmaceutical
US biopharma company Mineralys Therapeutics today announced the presentation of a new analysis from its pivotal Phase III Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg. 9 October 2026
Pharmaceutical
Israel-based Teva Pharmaceutical Industries US subsidiary today revealed that the US Food and Drug Administration (FDA) has approved Weltruza (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable (LAI) for the treatment of schizophrenia in adults. 9 October 2026
Biotechnology
Iambic Therapeutics, the San Diego-based AI drug discovery company, has set terms for a Nasdaq initial public offering of 9,375,000 shares priced at $15 to $17 each, under the proposed ticker IAM, according to an amended S-1 filed with the SEC Thursday. 9 October 2026
Pharmaceutical
When the World Health Organization (WHO) updates its Model List of Essential Medicines (EML), it gives governments a reference point for deciding which treatments their health systems should prioritize. Its choices can inform public purchasing and insurance coverage, although countries make their own decisions about what to fund. 9 October 2026
Biotechnology
The US Food and Drug Administration (FDA) has approved oche’s Tecentriq atezolizumab) and Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumor characterized by high mutation rates. 9 October 2026
Pharmaceutical
US pharma major Bristol Myers Squibb said its Phase III EXCALIBER-RRMM trial met its progression-free survival (PFS) endpoint, with Zenbexus (iberdomide) plus daratumumab and dexamethasone (ZDd) beating daratumumab, bortezomib and dexamethasone (DVd) in relapsed or refractory multiple myeloma, including patients at first relapse. 8 October 2026
Pharmaceutical
Privately-held US biopharma Cerevance said its Phase III ARISE trial of once-daily oral solengepras met its primary endpoint in Parkinson's disease patients with motor fluctuations on levodopa, and that it will meet the US Food and Drug Administration (FDA) to discuss the path to a potential New Drug Application. 8 October 2026
Pharmaceutical
Italian neuroscience company Newron Pharmaceuticals has set out the US Food and Drug Administration's (FDA) reasons for the clinical hold at US sites in its Phase III ENIGMA-TRS 2 trial of evenamide in treatment-resistant schizophrenia (TRS), and said it is preparing a response. 8 October 2026
Biotechnology
US biotech company MimiVax plans to discuss potential expedited regulatory pathways for its experimental cancer vaccine SurVaxM after a Phase IIb glioblastoma trial missed its primary endpoint but reported better outcomes in a prespecified group of younger patients. 8 October 2026
Latest In Brief for Astellas Pharma
Pharmaceutical
Spanish drugmaker PharmaMar has announced that health authorities in Canada, Qatar and South Korea have approved Zepzelca (lurbinectedin) in combination with atezolizumab (Roche’s Tecentriq) for the maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following first-line induction therapy with atezolizumab, carboplatin and etoposide. 25 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze